

Screened
N=690
Screen / Run-in Failures
N=341
Entry Criteria (284)
Withdrawn Consent (33)
Adverse Event (12)
Lost to Follow-up (5)
Investigator Decision (2)
Other (5)
Randomized
N=349
Statin Intolerant, N=177
Statin Tolerant, N=172
ETC-1002 120 mg
N=100
Statin Intolerant, N=51
Statin Tolerant, N=49
ETC-1002 180 mg
N=100
Statin Intolerant, N=51
Statin Tolerant, N=49
EZE 10 mg
N=99
Statin Intolerant, N=51
Statin Tolerant, N=48
ETC-1002 120 mg
+ EZE 10 mg
N=26
Statin Intolerant, N=12
Statin Tolerant, N=14
ETC-1002 180 mg
+ EZE 10 mg
N=24
Statin Intolerant, N=12
Statin Tolerant, N=12
Safety Pop., N=99*
mITT Pop., N=97
Completed, N=89
Discontinued, N=11
Safety Pop., N=100
mITT Pop., N=99
Completed, N=87
Discontinued, N=13
Safety Pop., N=99
mITT Pop., N=98
Completed, N=90
Discontinued, N=9
Safety Pop., N=26
mITT Pop., N=24
Completed, N=21
Discontinued, N=5
Safety Pop., N=24
mITT Pop., N=22
Completed, N=22
Discontinued, N=2

FIGURE 1



ETC-1002 120 mg
ETC-1002 180 mg
EZE 10 mg
ETC-1002 120 mg + EZE 10 mg
ETC-1002 180 mg + EZE 10 mg
Statin Tolerant
n=47 n=49 n=47 n=12 n=12
Statin Intolerant
n=50 n=50 n=51 n=12 n=10
LS Mean % Change in LDL-C from Baseline to week 12 End Point
0
-10
-20
-30
-40
-50
-60
*
†
‡
‡‡
‡‡‡

FIG. 2



LS Mean % Change in LDL-C from Baseline
0
-10
-20
-30
-40
-50
-60
0
2
4
8
12
Weeks on Treatment
-21%
-27%, p = 0.0008 vs.EZE
-30%, p < 0.0001 vs.EZE
-43%, p < 0.0001 vs.EZE
-48%, p < 0.0001 vs.EZE
ETC-1002 120 mg
ETC-1002 180 mg
EZE 10 mg
ETC-1002 120 mg + EZE 10 mg
ETC-1002 180 mg + EZE 10 mg

FIG. 3